<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Rituximab, a chimeric monoclonal antibody directed against CD20, has become a part of the standard therapy for patients with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> either in combination with other drugs or as a single agent </plain></SENT>
<SENT sid="1" pm="."><plain>The CD20 antigen is expressed on 95% of B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells and <z:mpath ids='MPATH_458'>normal</z:mpath> B-cells but, is not found on precursor B-cells or stem cells </plain></SENT>
<SENT sid="2" pm="."><plain>Rituximab is now approved for patients with diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> when combined with standard CHOP chemotherapy (<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi> and <z:chebi fb="0" ids="8382">prednisone</z:chebi>) or patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> who have failed first line chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>The monoclonal antibody is generally well tolerated </plain></SENT>
<SENT sid="4" pm="."><plain>Most of the adverse events are infusion-associated, mild to moderate non-hematological toxicities </plain></SENT>
<SENT sid="5" pm="."><plain>Severe respiratory adverse events have been infrequent </plain></SENT>
<SENT sid="6" pm="."><plain>Here, we report two patients with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in whom <z:hpo ids='HP_0006515'>interstitial pneumonitis</z:hpo> developed with rituximab therapy </plain></SENT>
</text></document>